Check for updates

OPEN ACCESS

EDITED BY Yibo Wu, Peking University, China

REVIEWED BY Andrew Clifton, University of Suffolk, United Kingdom Nur Melizza, Universitas Muhammadiyah Malang, Indonesia

*CORRESPONDENCE Shi Luo Noshi0604@126.com

RECEIVED 01 February 2025 ACCEPTED 12 March 2025 PUBLISHED 14 April 2025

CITATION

Mei Z, Cai C, Wang T, Zhang Y, Zhao W, Lam C, Luo S, Shi Y and Luo S (2025) Are mind-body therapies beneficial for older people with dementia? A Systematic Review and meta-analysis of randomized controlled trials. *Front. Psychiatry* 16:1569709. doi: 10.3389/fpsyt.2025.1569709

COPYRIGHT

© 2025 Mei, Cai, Wang, Zhang, Zhao, Lam, Luo, Shi and Luo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Are mind-body therapies beneficial for older people with dementia? A Systematic Review and meta-analysis of randomized controlled trials

Zhengyang Mei¹, Chenyi Cai¹, Tingfeng Wang², Yuanzhuo Zhang¹, Wen Zhao³, Chifong Lam⁴, Shulai Luo¹, Yu Shi¹ and Shi Luo^{1*}

¹School of Physical Education, Southwest University, Chongqing, China, ²School of Physical Education, Shanghai University of Sport, Shanghai, China, ³Faculty of Education, Southwest University, Chongqing, China, ⁴Key Laboratory of Cognition and Personality, Faculty of Psychology, Ministry of Education, Southwest University, Chongqing, China

Objective: This systematic review and meta-analysis aimed to evaluate the potential multidomain benefits of mind-body therapies (MBTs) for behavioral and psychological symptoms of dementia (BPSD) in older people with dementia (OPWD).

Methods: Relevant randomized controlled trials (RCTs) were identified using electronic databases and manual searches. Two independent researchers evaluated the risk of bias in the included trials using the Revised Cochrane Risk-of-Bias tool for randomized trials. A standardized mean difference (SMD) with a 95% confidence interval (CI) was used to combine effect sizes.

Results: This review included 35 RCTs comprising 4,043 patients, of whom 24 were included in the meta-analyses. MBTs effectively improved BPSD (SMD = -0.33; 95% CI -0.49 to -0.16; p < 0.01), anxiety (SMD = -0.82; 95% CI -1.53 to -0.10; p = 0.02), and depression (SMD = -0.57; 95% CI -1.06 to -0.08; p = 0.02), with no significant improvements observed in agitation (SMD = -0.09; 95% CI -0.25 to 0.07; p = 0.27) among patients with dementia. The certainty of evidence across the outcomes ranged from low to very low, based on the Grading of Recommendations, Assessment, Development, and Evaluations ratings.

Conclusion: Effective nursing for patients with dementia is vital, as they are undergoing a major transition in their physical and mental health. In clinical practice, healthcare and social care therapists should develop personalized intervention programs based on patient individual differences and the actual dose-response relationship, which will help maximize the clinical benefits of non-pharmacological treatments in the context of limited medical resources.

More high-quality RCTs could be conducted to compare the differential efficacy of non-pharmacological treatments on various aspects of BPSD in OPWD to provide a better evidence base to guide individual care and policy guidance.

Systematic review registration: PROSPERO, identifier CRD42024559809.

KEYWORDS

mind-body therapies, older people, dementia, mental health, gerontology

1 Introduction

Dementia is a progressive cognitive disorder that impairs daily functioning and is a primary contributor to dependency, disability, and death (1, 2). It is characterized by cognitive decline, deteriorating functional status, and worsening of neuropsychiatric symptoms (3). Currently, over 50 million individuals worldwide are affected by dementia, and projections indicate this figure could rise to 131 million by 2050 (3, 4). Moreover, the overall prevalence of dementia, from all causes, stands at 7.0%, with its rate of occurrence increasing sharply with age for both men and women (5), suggesting the growing public health challenge posed by dementia as the global population continues to age.

Old age is not only a critical stage for changes in physical and mental health but also a vulnerable period for the development of dementia. During this period, older people are often exposed to multiple risk factors for developing dementia, which are classified as immutable (age, sex, ethnicity, etc.) or potentially modifiable (diabetes, smoking, social isolation, physical inactivity, etc.) (6, 7). Moreover, compelling evidence suggests that dementia is prevalent among older people and may increase their susceptibility to physical and mental health problems, including cognitive impairment (8), suicidal behavior (9), epilepsy (10), disability (11), anxiety (12), and depression (13).

Dementia can be diagnosed based on medical history, cognitive and physical examination, laboratory testing, and brain imaging (3). As dementia is a progressive, incurable illness, several medications have been developed to help older people with dementia (OPWD) alleviate the physical and mental discomfort, including donepezil, cholinesterase inhibitors, memantine, and statins (14, 15). However, prolonged use of these drugs can result in numerous adverse outcomes. Specifically, the increasing use of cholinesterase inhibitors results in increased adverse drug reactions, such as cardiovascular and gastrointestinal adverse effects (16); treatment with antipsychotics in older people is associated with an increased risk of cardiovascular incidents and mortality (17). Therefore, no compelling evidence supports the use of these drugs in such patients (14).

In this regard, complementary therapies could offer potential solutions to these challenges. Mind-body therapies (MBTs), rooted in ancient Eastern practices, are a non-pharmacological approach that focuses on interactions between mind, body, and spirit to improve mental and physical well-being (18, 19). Compared with other medications, MBTs are characterized by low risk and high therapeutic benefits and can be alternatives or adjuvant approaches to conventional treatments (20, 21). Common MBTs include Mindfulness training, Tai Chi, Qigong, Baduanjin, Yoga, Pilates, and Music therapy, which have been proven to exert beneficial effects on the physical and mental health of OPWD (22–28). However, evidence regarding the efficacy of MBTs in managing the behavioral and psychological symptoms of dementia (BPSD) in OPWD is inconsistent, and some studies do not support the significant efficacy of MBTs in this area (29–33). This study aimed to evaluate the potential multidomain benefits of MBTs for BPSD in OPWD.

2 Methods

This systematic review and meta-analysis adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 (34) and was registered in the International Prospective Register of Systematic Reviews (PROSPERO) under the registration number CRD42024559809.

2.1 Search methods

Using Medical Subject Headings in conjunction with Boolean and proximity operators, a search was conducted across six electronic databases: PubMed, Embase, Web of Science, Scopus, EBSCOhost, and APA PsycINFO, to identify relevant literature. The search covered the period from the inception of each database up to June 2024, and the strategy adhered to the Population, Intervention, Comparator, Outcome, and Study design framework. Details of the search strategy are outlined in Table 1, as per the PubMed database.

2.2 Inclusion and exclusion criteria

The criteria for inclusion and exclusion of studies are presented in Table 2.

TABLE 1 PubMed search strategy.

#1	Dementia* [MeSH Terms]
#2	Dementia* [Title/Abstract] OR Alzheimer* [Title/Abstract] OR Amentia* [Title/Abstract]
#3	#1 OR #2
#4	Mind body* [Title/Abstract] OR Mind-body* [Title/Abstract] OR Mindfulness [Title/Abstract] OR Meditation [Title/Abstract] OR Shadow boxing [Title/ Abstract] OR Tai Ji [Title/Abstract] OR Tai-ji [Title/Abstract] OR Tai Chi [Title/Abstract] OR Chi, Tai [Title/Abstract] OR Tai Ji Quan [Title/Abstract] OR Ji Quan, Tai [Title/Abstract] OR Quan, Tai Ji [Title/Abstract] OR Taiji [Title/Abstract] OR Taiji [Title/Abstract] OR Tai Chi [Title/Abstract] OR Tai Chi [Title/Abstract] OR Tai Chi [Title/Abstract] OR Tai I Chi Chuan [Title/Abstract] OR Qigong [Title/Abstract] OR Qi Gong [Title/Abstract] OR Ch'i Kung [Title/Abstract] OR Baduanjin [Title/Abstract] OR Yoga [Title/Abstract] OR Pilates [Title/Abstract] OR Exercise Movement Techniques [Title/Abstract] OR Movement Techniques, Exercise [Title/Abstract] OR Exercises Movement Technics [Title/Abstract] OR Pilates-Based Exercises [Title/Abstract] OR Exercises, Pilates-Based [Title/Abstract] OR Pilates Based Exercises [Title/Abstract] OR Pilates Training [Title/Abstract] OR Training, Pilates [Title/Abstract] OR Music* [Title/Abstract]
#5	Older* [Title/Abstract] OR Elder* [Title/Abstract] OR Senior* [Title/Abstract] OR Aged [Title/Abstract]
#6	Randomized controlled trial [Publication Type] OR Randomized [Title/Abstract] OR Placebo [Title/Abstract]
#7	#3 AND #4 AND #5 AND #6

2.3 Study selection and guality appraisal

Two independent researchers, following predefined inclusion and exclusion criteria, utilized EndNote 20.6 for study selection. After duplicates were eliminated, the remaining references were independently reviewed by both researchers based on titles, abstracts, and full texts. Quality appraisal of the included trials was conducted using the Revised Cochrane risk-of-bias tool for randomized trials, with evaluation across five bias domains: (a) randomization process, (b) deviations from intended interventions, (c) missing outcome data, (d) measurement of the outcome, and (e) selection of the reported result (35). Disagreements during study selection and quality appraisal processes were resolved through consultation with a third author.

2.4 Data extraction

Two independent researchers used a data extraction form to gather relevant information from each included trial. The extracted data comprised the following: (1) basic details such as the first author, country, and year of publication; (2) participant characteristics, including mean age (with standard deviation), sample size, and the percentage of male participants; (3)

Category	Inclusion criteria	Exclusion criteria
Population	Older people with dementia (age 60 years or older)	Not older people with dementia
Intervention	Mind-body therapies were used as the generic term for interventions including Mindfulness training, Tai Chi, Qigong, Baduanjin, Yoga, Pilates, Music therapy, etc	Interventions that were not mind-body therapies
Comparator	Control group receiving only routine treatment or appropriate rehabilitation intervention	No exclusion criteria
Outcome	Any assessment for behavioral and psychological symptoms of dementia	No exclusion criteria
Study design	All types of randomized controlled trials	Non-randomized controlled trials, such as uncontrolled before-after trials, quasi-experiments, literature review, study protocols, conference proceedings, comments, editorial, letter to editors, etc

TABLE 2 Inclusion and exclusion criteria.

2.5 Data synthesis

conditions; and (5) outcome and measure.

Given the differences in the measurement scales used for continuous variables (BPSD, anxiety, depression, and agitation) across the included trials, standardized mean differences (SMDs; Cohen's d) with 95% confidence intervals (CIs) for each outcome were pooled and presented in forest plots using Stata software, version 18.0 (36). Statistical heterogeneity between trials was assessed using the chi-square test based on Q-test and I^2 statistics, with a significance threshold of *p*-value < 0.10 (37). A sensitivity analysis was performed for each outcome using a stepwise elimination method to assess whether the pooled results were significantly affected by individual studies (36). Given the number of included trials, publication bias was examined by visual inspection of funnel plots and using Egger's test (38, 39). The trim-and-fill method was used to assess the robustness of the findings in the presence of a publication bias (40). The certainty of evidence for each outcome was evaluated by two independent researchers using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) guidelines (41). All statistical analyses were performed using Stata 18.0.

diagnostic criteria for dementia; (4) intervention and control

3 Results

3.1 Search outcomes

Searches of electronic databases and additional sources yielded 2,120 results, of which 918 were duplicates. After the titles and abstracts of the remaining 1,202 records were screened, the full text of 441 articles was assessed, resulting in 35 eligible randomized controlled trials (RCTs) (42–76). After 11 additional trials with missing quantitative data were excluded, 24 were included in the meta-analyses. A PRISMA flow diagram of the literature search is presented in Figure 1.

3.2 Study characteristics

The 35 included trials (see Table 3) were published between 2006 and 2024 and were conducted in various countries, including China (13 trials), Italy (6 trials), the United States (4 trials), Australia (3 trials), Germany (2 trials), the Netherlands (2 trials), the United Kingdom (2 trials), Denmark, France, and Japan (one trial each). In total, 2,065 patients were assigned to the experimental group, with a

mean age ranging from 76.78 to 86.56 years, while 1,978 patients were assigned to the control group, with a mean age of 76.80 to 87.20 years.

Among the 35 included trials, the diagnostic criteria for dementia primarily consisted of medical diagnosis, Diagnostic and Statistical Manual of Mental Disorders-IV, Mini-Mental State Examination, Clinical Dementia Rating, and the Global Deterioration Scale. The interventions included personalized music (11 trials), group music (9 trials), traditional music (6 trials), mindfulness (3 trials), music with movement (3 trials), Tai Chi (2 trials), and yoga (1 trial). The controls included treatment as usual (25 trials), standard care (8 trials), nointervention (1 trial), and wait-list (1 trial). In addition, the deliverers of the intervention primarily included music therapists, musicians, nursing staff, psychotherapist, and trained facilitators, all of whom were qualified to be responsible for the implementation of the intervention.

3.3 Quality appraisal

The risk of bias ranged from some concern to high (see Figure 2, Table 4). The main flaws (≥10% high risk) across the included trials



Study ID	Country	Population	Age (Mean (SD))	Total/M%	Diagnostic criteria	Intervention	Control	Outcome (measure)
Baker et al., 2022 (42)	Australia	OPWD	T: 86.00 (7.50) C: 87.20 (6.50)	T: 45/NR C: 50/NR	CDR/MMSE	Group music	SC	Depression (MADRS) BPSD (NPI)
Ceccato et al., 2012 (43)	Italy	OPWD	T: 85.50 (5.90) C: 87.20 (7.10)	T: 27/22.2% C: 23/17.4%	DSM-IV	Traditional music	SC	Depression (GDS) Agitation (CMAI)
Chen and Pei, 2018 (44)	China	OPWD	T: 77.30 (9.40) C: 77.30 (10.00)	T: 15/40.0% C: 13/61.5%	Medical diagnosis/ MMSE/CDR	Traditional music	TAU	Agitation (CMAI)
Cheng et al., 2012 (45)	China	OPWD	T: 81.00 (7.70) C: 82.50 (7.10)	T: 12/50.0% C: 12/25.0%	MMSE/CDR	Tai Chi	TAU	Depression (GDS)
Cheung et al., 2020 (46)	China	OPWD	T: 85.71 (6.68) C: 85.58 (7.46)	T: 58/25.9% C: 53/24.5%	Medical diagnosis/ Global Deterioration Scale	Music with movement	TAU	Agitation (CMAI)
Chu et al., 2014 (47)	China	OPWD	T+C: 82.00 (6.80)	T: 49/NR C: 51/NR	DSM-IV	Group music	TAU	Depression (CSDD)
Churcher Clarke et al., 2017 (66)	UK	OPWD	T: 81.30 (9.29) C: 79.36 (9.91)	T: 20/40.0% C: 11/72.7%	Medical diagnosis/ MMSE/DSM-IV	Mindfulness	TAU	Anxiety (RAID) Depression (CSDD)
Cooke et al., 2010a (48)	Australia	OPWD	T: NR C: NR	T: 24/NR C: 23/NR	Medical diagnosis/ MMSE/DSM-IV	Group music	TAU	Depression (GDS)
Cooke et al., 2010b (49)	Australia	OPWD	T: NR C: NR	T: 24/NR C: 23/NR	Medical diagnosis/ MMSE/DSM-IV	Group music	TAU	Anxiety (RAID) Agitation (CMAI)
Giulietti et al., 2023 (67)	Italy	OPWD	T: 82.80 (5.60) C: 82.90 (4.20)	T: 22/36.4% C: 22/22.7%	NINCDS-ADRDA	Mindfulness	No- intervention	Depression (BDI)
Guétin et al., 2009 (50)	France	OPWD	T: 85.20 (6.00) C: 86.90 (5.20)	T: 14/NR C: 12/NR	Medical diagnosis	Personalized music	TAU	Anxiety (HAMA) Depression (GDS)
Harrison et al., 2021 (68)	USA	OPWD	T: 79.70 (11.20) C: 80.60 (12.60)	T: 103/28.4% C: 55/38.0%	Medical diagnosis	Personalized music	TAU	Agitation (CMAI)
Hillebrand et al., 2023 (51)	Germany	OPWD	T: 83.84 (7.25) C: 84.00 (6.69)	T: 44/18.2% C: 46/26.1%	Medical diagnosis	Personalized music	TAU	BPSD (DeCS)
Huang et al., 2019 (52)	China	OPWD	T: 81.90 (6.00) C: 81.90 (6.10)	T: 36/NR C: 38/NR	DSM-IV/CDR	Tai Chi	TAU	Depression (GDS) BPSD (NPI)
Lin et al., 2011 (53)	China	OPWD	T: 81.46 (7.34) C: 82.15 (6.28)	T: 49/46.9% C: 51/47.1%	DSM-IV	Group music	TAU	Agitation (CMAI)
Liu et al., 2021 (54)	China	OPWD	T: 86.56 (4.54) C: 86.92 (5.73)	T: 25/NR C: 25/NR	CDR	Music with movement	TAU	Anxiety (HAMA) Depression (GDS)
Lyu et al., 2018 (55)	China	OPWD	T: 68.90 (7.10) C: 69.90 (7.90)	T: 97/41.2% C: 95/41.1%	NINCDS-ADRDA	Traditional music	TAU	BPSD (NPI)
McCreedy et al., 2022 (69)	USA	OPWD	T: 79.80 (12.20) C: 80.80 (12.10)	T: 483/32.3% C: 493/29.2%	Medical diagnosis	Personalized music	TAU	Agitation (CMAI)
Noone et al., 2023 (70)	UK	OPWD	T: 77.80 (10.63) C: 76.80 (4.96)	T: 10/10.0% C: 10/40.0%	DSM-IV/ MMSE/PHQ	Mindfulness	TAU	Anxiety (RAID) Depression (CSDD)

TABLE 3 Main characteristics of the included randomized controlled trials.

(Continued)

TABLE 3 Continued

Study ID	Country	Population	Age (Mean (SD))	Total/M%	Diagnostic criteria	Intervention	Control	Outcome (measure)
Park et al., 2020 (56)	USA	OPWD	T+C: 84.30 (7.70)	T: 10/NR C: 10/NR	Medical diagnosis/MMSE	Yoga	TAU	Anxiety (HADS) Depression (HADS) Agitation (CMAI)
Prick et al., 2024 (71)	Netherlands	OPWD	T: 81.70 (7.60) C: 82.30 (9.90)	T: 49/38.8% C: 53/45.3%	Medical diagnosis	Personalized music	TAU	BPSD (NPI)
Raglio et al., 2015 (57)	Italy	OPWD	T: 81.70 (7.80) C: 82.40 (6.80)	T: 32/NR C: 35/NR	DSM-IV/CDR/ MMSE/NPI	Personalized music	SC	BPSD (NPI)
Raglio et al., 2010a (58)	Italy	OPWD	T: 85.40 (6.50) C: 84.60 (6.80)	T: 30/3.3% C: 30/13.3%	Medical diagnosis/ MMSE/DSM-IV	Traditional music	SC	BPSD (NPI)
Raglio et al., 2010b (72)	Italy	OPWD	T: 84.00 (6.00) C: 87.00 (6.00)	T: 10/20.0% C: 10/30.0%	NINCDS-ADRDA NINDS-AIREN	Traditional music	SC	BPSD (NPI)
Raglio et al., 2008 (73)	Italy	OPWD	T: 84.40 (5.50) C: 85.80 (5.40)	T: 30/16.6% C: 29/13.8%	DSM-IV/ MMSE/CDR	Traditional music	SC	BPSD (NPI)
Ridder et al., 2013 (59)	Denmark	OPWD	T: 82.17 (8.84) C: 80.20 (8.67)	T: 20/NR C: 21/NR	Medical diagnosis/ MMSE/Global Deterioration Scale	Personalized music	SC	Agitation (CMAI)
Sakamoto et al., 2013 (60)	Japan	OPWD	T: 80.40 (7.41) C: 81.54 (7.82)	T: 13/15.4% C: 13/15.4%	DSM-IV/ MMSE/CDR	Personalized music	TAU	BPSD (BEHAVE-AD)
Sing et al., 2019 (61)	China	OPWD	T: 85.00 (7.10) C: 85.70 (7.00)	T: 40/30.0% C: 33/30.3%	Medical diagnosis	Group music	SC	BPSD (NPI)
Sisti et al., 2024 (74)	USA	OPWD	T: 79.80 (12.20) C: 80.80 (12.10)	T: 483/32.3% C: 493/29.2%	Medical diagnosis	Personalized music	TAU	BPSD (ABMI)
Sung et al., 2006a (62)	China	OPWD	T: NR C: NR	T: 32/NR C: 25/NR	Medical diagnosis	Personalized music	TAU	Agitation (CMAI)
Sung et al., 2006b (63)	China	OPWD	T: 76.78 (9.12) C: 78.44 (7.85)	T: 18/61.1% C: 18/83.3%	DSM-IV/Global Deterioration Scale	Music with movement	TAU	Agitation (CMAI)
Sung et al., 2012 (64)	China	OPWD	T: 81.37 (9.14) C: 79.50 (8.76)	T: 27/NR C: 28/NR	Medical diagnosis	Group music	TAU	Anxiety (RAID) Agitation (CMAI)
Vink et al., 2013 (75)	Netherlands	OPWD	T: 82.42 (7.62) C: 81.76 (5.72)	T: 43/32.6% C: 34/26.5%	DSM-IV	Group music	TAU	Agitation (CMAI)
Weise et al., 2020 (76)	Germany	OPWD	T+C: 85.05 (5.93)	T: 10/NR C: 10/NR	Medical diagnosis	Personalized music	Wait-list	Agitation (CMAI)
Xu et al., 2024 (65)	China	OPWD	T: NR C: NR	T: 61/52.5% C: 60/55.0%	Medical diagnosis	Group music	TAU	Depression (CSDD)

T, Test group; C, Control group; M%, Percentage of males; OPWD, Older People with Dementia; TAU, Treatment as usual; SC, Standard care; ABMI, Agitated Behavior Mapping Instrument; BPSD, Behavioral and Psychological Symptoms of Dementia; BDI, Beck Depression Inventory; BEHAVE-AD, Behavioral Pathology in Alzheimer's Disease Rating Scale; CDR, Clinical Dementia Rating; CSDD, Cornell Scale for Depression in Dementia; CMAI, Cohen-Mansfield Agitation Inventory; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders-IV; DeCS, Dementia Coding System; GDS, Geriatric Depression Scale; HAMA, Hamilton Anxiety Rating Scale; HADS, Hospital Anxiety and Depression Rating, MMSE, Mini-Mental State Examination; MADRS, Montgomery-Asberg Depression Rating Scale; NIN, Neuropsychiatric Inventory; NINCDS-ADRDA, National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association; NINDS-AIREN, National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l'Enseignement en Neurosciences; PHQ, Patient Health Questionnaire; RAID, Rating Anxiety in Dementia Scale.

were the randomization process (94.3% low risk, 5.7% some concerns, and 0.0% high risk); deviations from intended interventions (45.7% low risk, 54.3% some concerns, and 0.0% high risk); missing outcome data (48.6% low risk, 48.6% some concerns, and 2.8% high risk); outcome measurement (97.2% low risk, 2.8% some concerns, and 0.0% high risk); and selection of the reported results (14.3% low risk, 77.1% some concerns, and 8.6% high risk).

3.4 Pairwise meta-analyses 3.4.1 Effects of MBTs on BPSD

A meta-analysis of 7 RCTs (N = 564 patients) exhibited a significant improvement in BPSD (SMD = -0.33; 95% CI -0.49 to -0.16; p < 0.01) in OPWD, with no significant heterogeneity between RCTs ($I^2 = 43.68\%$; Q = 10.65; p = 0.10). A forest plot for BPSD is presented in Figure 3.



TABLE 4 Risk of bias summary for the included effect estimates.

	Outcomo	Domains	Domains								
	Outcome	D1	D2	D3	D4	D5	Overall rating				
Baker et al., 2022 (42)	Depression	Low	Low	Some concerns	Low	Some concerns	Some concerns				
Baker et al., 2022 (42)	BPSD	Low	Low	Some concerns	Low	Some concerns	Some concerns				
Ceccato et al., 2012 (43)	Depression	Low	Some concerns	Low	Low	Low	Some concerns				
Ceccato et al., 2012 (43)	Agitation	Low	Some concerns	Low	Low	Low	Some concerns				
Chen and Pei, 2018 (44)	Agitation	Low	Low	Some concerns	Low	Low	Some concerns				
Cheng et al., 2012 (45)	Depression	Low	Some concerns	Low	Low	Some concerns	Some concerns				
Cheung et al., 2020 (46)	Agitation	Low	Low	Low	Low	Some concerns	Some concerns				
Chu et al., 2014 (47)	Depression	Low	Low	Low	Low	Some concerns	Some concerns				
Churcher Clarke et al., 2017 (66)	Anxiety	Low	Some concerns	Some concerns	Low	Some concerns	Some concerns				
Churcher Clarke et al., 2017 (66)	Depression	Low	Some concerns	Some concerns	Low	Some concerns	Some concerns				
Cooke et al., 2010a (48)	Depression	Low	Low	Some concerns	Low	Some concerns	Some concerns				
Cooke et al., 2010b (49)	Anxiety	Low	Low	Some concerns	Low	Some concerns	Some concerns				
Cooke et al., 2010b (49)	Agitation	Low	Low	Some concerns	Low	Some concerns	Some concerns				
Giulietti et al., 2023 (67)	Depression	Low	Some concerns	Low	Low	Some concerns	Some concerns				
Guétin et al., 2009 (50)	Anxiety	Low	Low	Some concerns	Low	Some concerns	Some concerns				
Guétin et al., 2009 (50)	Depression	Low	Low	Some concerns	Low	Some concerns	Some concerns				
Harrison et al., 2021 (68)	Agitation	Low	Some concerns	Some concerns	Low	Some concerns	Some concerns				
Hillebrand et al., 2023 (51)	BPSD	Low	Some concerns	High	Some concerns	Low	High				
Huang et al., 2019 (52)	Depression	Low	Some concerns	Some concerns	Low	Some concerns	Some concerns				
Huang et al., 2019 (52)	BPSD	Low	Some concerns	Some concerns	Low	Some concerns	Some concerns				
Lin et al., 2011 (53)	Agitation	Low	Some concerns	Low	Low	Some concerns	Some concerns				
Liu et al., 2021 (54)	Anxiety	Low	Some concerns	Low	Low	Some concerns	Some concerns				
Liu et al., 2021 (54)	Depression	Low	Some concerns	Low	Low	Some concerns	Some concerns				
Lyu et al., 2018 (55)	BPSD	Low	Some concerns	Low	Low	Some concerns	Some concerns				
McCreedy et al., 2022 (69)	Agitation	Low	Low	Some concerns	Low	Some concerns	Some concerns				

(Continued)

TABLE 4 Continued

	Outcome	Domains					
Study ID	Outcome	D1	D2	D3	D4	D5	Overall rating
Noone et al., 2023 (70)	Anxiety	Low	Low	Some concerns	Low	Some concerns	Some concerns
Noone et al., 2023 (70)	Depression	Low	Low	Some concerns	Low	Some concerns	Some concerns
Park et al., 2020 (56)	Anxiety	Low	Low	Some concerns	Low	Some concerns	Some concerns
Park et al., 2020 (56)	Depression	Low	Low	Some concerns	Low	Some concerns	Some concerns
Park et al., 2020 (56)	Agitation	Low	Low	Some concerns	Low	Some concerns	Some concerns
Prick et al., 2024 (71)	BPSD	Low	Low	Low	Low	High	High
Raglio et al., 2015 (57)	BPSD	Low	Low	Some concerns	Low	Some concerns	Some concerns
Raglio et al., 2010a (58)	BPSD	Low	Some concerns	Some concerns	Low	High	High
Raglio et al., 2010b (72)	BPSD	Low	Some concerns	Low	Low	Low	Some concerns
Raglio et al., 2008 (73)	BPSD	Low	Some concerns	Some concerns	Low	High	High
Ridder et al., 2013 (59)	Agitation	Low	Low	Low	Low	Some concerns	Some concerns
Sakamoto et al., 2013 (60)	BPSD	Low	Some concerns	Low	Low	Some concerns	Some concerns
Sing et al., 2019 (61)	BPSD	Some concerns	Low	Some concerns	Low	Some concerns	Some concerns
Sisti et al., 2024 (74)	BPSD	Low	Low	Some concerns	Low	Some concerns	Some concerns
Sung et al., 2006a (62)	Agitation	Low	Some concerns	Low	Low	Low	Some concerns
Sung et al., 2006b (63)	Agitation	Low	Some concerns	Low	Low	Some concerns	Some concerns
Sung et al., 2012 (64)	Anxiety	Low	Some concerns	Low	Low	Some concerns	Some concerns
Sung et al., 2012 (64)	Agitation	Low	Some concerns	Low	Low	Some concerns	Some concerns
Vink et al., 2013 (75)	Agitation	Low	Low	Some concerns	Low	Some concerns	Some concerns
Weise et al., 2020 (76)	Agitation	Some concerns	Some concerns	Low	Low	Some concerns	Some concerns
Xu et al., 2024 (65)	Depression	Low	Some concerns	Low	Low	Some concerns	Some concerns

BPSD, Behavioral and Psychological Symptoms of Dementia; D1, Randomization process; D2, Deviations from intended interventions; D3, Missing outcome data; D4, Measurement of the outcome; D5, Selection of the reported result.

Green for "low risk," yellow for "some concerns," and red for "high risk".



Main analyses for the effects of MBTs on BPSD.

	Treatment			Contro	ol		Std. Mean Difference	Weight	
Anxiety	Ν	Mean	SD	N	Mean	SD		with 95% CI	(%)
Cooke et al. 2010b	24	7.50	8.57	23	9.26	8.51		-0.21 [-0.78, 0.37]	18.02
Guétin et al. 2009	14	8.40	3.70	12	20.80	6.20		-2.48 [-3.50, -1.45]	14.37
Liu et al. 2021	25	10.20	1.94	25	12.96	1.21	_ _	-1.71 [-2.35, -1.06]	17.46
Park et al. 2020	10	8.50	6.40	10	6.78	3.42	¦ <u> </u> +●	0.34 [-0.55, 1.22]	15.55
Sakamoto et al. 2013	13	.30	.60	13	1.20	1.70		-0.71 [-1.50, 0.09]	16.30
Sung et al. 2012	27	3.89	4.02	28	5.36	4.34		-0.35 [-0.88, 0.18]	18.31
Overall								-0.82 [-1.53, -0.10]	
Heterogeneity: $t^2 = 0.65$	$, I^2 = 8$	3.69%, H	$I^2 = 6.1$	3					
Test of $q_i = q_j$: $Q(5) = 30$	0.66, p	= 0.00							
Test of $q = 0$: $z = -2.24$	p = 0.	02							
Random-effects DerSir	nonian-	-Laird m	nodel				-3 -2 -1 0 1		
						F	avors Experimental Favors C	ontrol	
yses for the effects of MB	Ts on	anxiety.							

3.4.2 Effects of MBTs on anxiety

A meta-analysis of 6 RCTs (N = 224 patients) exhibited a significant improvement in anxiety (SMD = -0.82; 95% CI -1.53 to -0.10; p = 0.02) in OPWD, but with significant heterogeneity between RCTs ($I^2 = 83.69\%$; Q = 30.66; p < 0.01). A forest plot for anxiety is presented in Figure 4.

3.4.3 Effects of MBTs on depression

A meta-analysis of 10 RCTs (N = 607 patients) exhibited a significant improvement in depression (SMD = -0.57; 95% CI -1.06 to -0.08; p = 0.02) in OPWD, but with significant heterogeneity between RCTs ($I^2 = 87.39\%$; Q = 71.40; p < 0.01). A forest plot for depression is presented in Figure 5.

3.4.4 Effects of MBTs on agitation

A meta-analysis of 11 RCTs (N = 618 patients) exhibited no significant improvement in agitation (SMD = -0.09; 95% CI -0.25 to 0.07; p = 0.27) in OPWD, with no significant heterogeneity between RCTs ($I^2 = 34.66\%$; Q = 15.31; p = 0.12). A forest plot for agitation is presented in Figure 6.

3.5 Sensitivity analyses

The results of the sensitivity analyses indicated that the pooled results for agitation and BPSD remained stable after excluding individual studies, indicating that these results were robust and insensitive to study selection. However, the pooled results for

D		Treatme	m		Confid	1		Std. Mean Difference	weight
Depression	Ν	Mean	SD	Ν	Mean	SD		with 95% CI	(%)
Baker et al. 2022	45	12.00	8.70	50	13.70	7.80		-0.21 [-0.61, 0.20]	10.91
Ceccato et al. 2012	27	9.66	3.34	23	8.96	4.94	¦↓●	0.17 [-0.39, 0.73]	10.22
Cheng et al. 2012	12	7.75	2.83	12	9.17	2.76		0.51 [-1.32, 0.30]	8.89
Chu et al. 2014	49	8.22	7.12	51	13.78	9.59	_	-0.66 [-1.06, -0.25]	10.91
Cooke et al. 2010a	24	3.50	3.34	23	3.26	2.29	 	0.08 [-0.49, 0.66]	10.15
Guétin et al. 2009	14	8.90	3.30	12	11.20	6.10		-0.48 [-1.26, 0.30]	9.05
Huang et al. 2019	36	2.44	1.04	38	5.37	1.89	— —	-1.91 [-2.46, -1.36]	10.26
Liu et al. 2021	25	4.44	.65	25	4.60	.65		0.25 [-0.80, 0.31]	10.22
Park et al. 2020	10	8.38	4.07	10	8.33	5.00	_ _	0.01 [-0.87, 0.89]	8.55
Xu et al. 2024	61	3.94	1.55	60	8.02	2.86	_ —	-1.78 [-2.20, -1.36]	10.84
Overall								-0.57 [-1.06, -0.08]	
Heterogeneity: $t^2 = 0$.	53, $I^2 =$	87.39%	$, H^2 = $	7.93					
Test of $q_i = q_j$: Q(9) =	71.40,	p = 0.00)						
Test of $q = 0: z = -2.2$	28, p =	0.02							
Random-effects Der	Random-effects DerSimonian-Laird model						-2 -1 0	1	
						Far	ors Experimental Fa	avors Control	

	Treatment			Contro	ol.		Std. Mean Difference	Weight	
Agitation	Ν	Mean	SD	N	Mean	SD		with 95% CI	(%)
Ceccato et al. 2012	27	25.63	11.89	23	22.80	11.65		0.24 [-0.32, 0.80]	8.12
Chen and Pei 2018	15	41.90	13.40	13	39.00	15.70		0.20 [-0.54, 0.94]	4.56
Cheung et al. 2020	58	33.53	14.43	53	33.33	11.84	 	0.02 [-0.36, 0.39]	18.24
Cooke et al. 2010b	24	1.65	.63	23	1.70	.61		-0.08 [-0.65, 0.49]	7.73
Lin et al. 2011	49	35.89	8.53	51	38.25	10.85	•II	-0.24 [-0.63, 0.15]	16.34
Park et al. 2020	10	53.25	16.27	10	45.33	11.96		0.55 [-0.34, 1.45]	3.17
Ridder et al. 2013	20	22.35	15.44	21	26.47	15.10	+	-0.27 [-0.89, 0.35]	6.68
Sing et al. 2019	40	1.40	2.00	33	1.80	2.60	• 	-0.17 [-0.64, 0.29]	11.86
Sung et al. 2006a	32	60.53	10.37	25	67.16	12.54		-0.58 [-1.12, -0.05]	8.87
Sung et al. 2006b	18	3.44	1.29	18	4.50	1.65	+	-0.72 [-1.39, -0.04]	5.57
Sung et al. 2012	27	32.7	4.98	28	31.00	2.96		0.42 [-0.12, 0.95]	8.86
Overall							+	-0.09 [-0.25, 0.07]	
Heterogeneity: $I^2 = 34$.	.66%,	$H^2 = 1.53$	3				ij		
Test of $q_i = q_j$: Q(10) =	= 15.31	, p = 0.1	2						
Test of $q = 0$: $z = -1.1$	1, p =	0.27							
Fixed-effects inverse-	-variar	nce mode	el				-15 0 .5 1		
						Favor	s Experimental Favors Control		
	DT								

TABLE 5 Sensitivity analyses for outcomes by omitting individual studies.

			95%	6 CI
Outcome	Study omitted	SMD	Lower bound	Upper bound
	Baker et al., 2022 (42)	-0.37	-0.56	-0.19
	Hillebrand et al., 2023 (51)	-0.34	-0.53	-0.16
	Huang et al., 2019 (52)	-0.27	-0.45	-0.09
BPSD	Lyu et al., 2018 (55)	-0.29	-0.50	-0.08
	Raglio et al., 2015 (57)	-0.37	-0.55	-0.20
	Raglio et al., 2010b (72)	-0.34	-0.51	-0.17
	Sakamoto et al., 2013 (60)	-0.29	-0.46	-0.12
	Cooke et al., 2010b (49)	-0.95	-1.81	-0.09
	Guétin et al., 2009 (50)	-0.54	-1.18	0.09
Americator	Liu et al., 2021 (54)	-0.62	-1.32	0.09
Anxiety	Park et al., 2020 (56)	-1.02	-1.78	-0.27
	Sakamoto et al., 2013 (60)	-0.84	-1.70	0.01
	Sung et al., 2012 (64)	-0.93	-1.82	-0.03
	Baker et al., 2022 (42)	-0.61	-1.16	-0.07
Depression	Ceccato et al., 2012 (43)	-0.65	-1.16	-0.14
Depression	Cheng et al., 2012 (45)	-0.57	-1.10	-0.05
	Chu et al., 2014 (47)	-0.56	-1.13	0.01

TABLE 5 Continued

			95%	6 CI
Outcome	Study omitted	SMD	Lower bound	Upper bound
	Cooke et al., 2010a (48)	-0.64	-1.16	-0.13
	Guétin et al., 2009 (50)	-0.58	-1.11	-0.05
	Huang et al., 2019 (52)	-0.42	-0.88	0.04
	Liu et al., 2021 (54)	-0.60	-1.14	-0.07
	Park et al., 2020 (56)	-0.62	-1.14	-0.11
	Xu et al., 2024 (65)	-0.43	-0.85	0.01
	Ceccato et al., 2012 (43)	-0.12	-0.29	0.05
	Chen and Pei, 2018 (44)	-0.10	-0.27	0.06
	Cheung et al., 2020 (46)	-0.11	-0.29	0.06
	Cooke et al., 2010b (49)	-0.09	-0.26	0.07
	Lin et al., 2011 (53)	-0.06	-0.23	0.11
Agitation	Park et al., 2020 (56)	-0.11	-0.27	0.05
	Ridder et al., 2013 (59)	-0.08	-0.24	0.09
	Sing et al., 2019 (61)	-0.08	-0.25	0.09
	Sung et al., 2006a (62)	-0.04	-0.21	0.12
	Sung et al., 2006b (63)	-0.05	-0.22	0.11
	Sung et al., 2012 (64)	-0.14	-0.31	0.03

SMD, Standardized mean difference; CI, Confidence interval; BPSD, Behavioral and Psychological Symptoms of Dementia.

(Continued)



anxiety and depression were sensitive to study selection and were less robust when individual studies were excluded. The results of the sensitivity analyses are presented in Table 5.

3.6 Publication bias and certainty of evidence

Given the number of included trials with pooled results for depression and agitation, publication bias was assessed using funnel plots and the Egger's test. Funnel plots for depression and agitation are presented symmetrically in Figure 7. The *p*-values of Egger's test for depression and agitation were 0.42 and 0.55, respectively, indicating that publication bias did not affect this type of study. According to the GRADE ratings, the certainty of evidence across the outcomes ranged from low to very low, owing to inconsistency, indirectness, imprecision, and publication bias (see Table 6).

4 Discussion

Previous studies have predominantly investigated the efficacy of single interventions for OPWD and have provided inconsistent evidence regarding various outcomes (23–33). This study aimed to evaluate the potential multidomain benefits of MBTs for BPSD in OPWD. The pooled results of the meta-analyses indicated that MBTs effectively improved BPSD (SMD = -0.33; 95% CI -0.49 to -0.16; p < 0.01), anxiety (SMD = -0.82; 95% CI -1.53 to -0.10; p = 0.02), and depression (SMD = -0.57; 95% CI -1.06 to -0.08; p = 0.02), with no significant improvements observed in agitation (SMD = -0.09; 95% CI -0.25 to 0.07; p = 0.27) among patients with dementia.

Music-based interventions are likely the most common MBT for alleviating BPSD in OPWD, as evidenced in 26 of the 35 trials. Previous studies have confirmed the effectiveness of music-based

Outcome	Risk of bias	Inconsistency	Indirectness	Imprecision	Publication bias	Certainty of the evidence
BPSD	No downgrade, as trials at high risk of bias constituted less than 30%.	Downgrade by one level due to unexplained inconsistency (I^2 = 43.68%).	Downgrade by one level due to the inclusion of certain participants (OPWD).	No concerns (SMD = -0.33; 95% CI -0.49 to -0.16).	/	⊕⊕⊝⊝ Low
Anxiety	No downgrade, as trials at high risk of bias constituted less than 30%.	Downgrade by two levels due to unexplained inconsistency (I^2 = 83.69%).	Downgrade by one level due to the inclusion of certain participants (OPWD).	No concerns (SMD = -0.82; 95% CI -1.53 to -0.10).	1	⊕⊝⊝⊝ Very low
Depression	No downgrade, as trials at high risk of bias constituted less than 30%.	Downgrade by two levels due to unexplained inconsistency (I^2 = 87.39%).	Downgrade by one level due to the inclusion of certain participants (OPWD).	No concerns (SMD = -0.57; 95% CI -1.06 to -0.08).	No publication bias is suspected.	⊕⊝⊝⊝ Very low
Agitation	No downgrade, as trials at high risk of bias constituted less than 30%.	Downgrade by one level due to unexplained inconsistency (I^2 = 34.66%).	Downgrade by one level due to the inclusion of certain participants (OPWD).	Some concerns (SMD = -0.09; 95% CI -0.25 to 0.07). Downgrade by one level.	No publication bias is suspected.	⊕⊖⊝⊖ Very low

TABLE 6 Certainty of evidence rating (GRADE).

SMD, Standardized mean difference; CI, Confidence interval; I², Heterogeneity index in percentage (range: 0-100%); BPSD, Behavioral and Psychological Symptoms of Dementia; OPWD, Older People with Dementia.

interventions, particularly in improving anxiety and depression (77-81). Music-based interventions are among the most effective approaches for managing BPSD in OPWD. However, a recent systematic review revealed that music-based interventions may not have achieved the anticipated efficacy, suggesting that the generalizability and applicability of this evidence require further examination (82). Overall, MBTs have significant therapeutic benefits in alleviating BPSD in OPWD, and the underlying mechanisms may be explained from several perspectives. Dementia is associated with the hypothalamus-pituitary-adrenal (HPA) axis and the autonomic nervous system (ANS), which are the main components of emotional regulation (83, 84). By reducing the HPA axis activation and reactivity, MBTs may alleviate the effects of stress and foster multiple positive downstream effects by shifting the ANS balance from primarily sympathetic to parasympathetic, leading to positive changes in cardiac vagal function, mood, energy state, and related neuroendocrine, metabolic, and inflammatory responses (85-89), which may play a potential role in mediating BPSD in OPWD. In addition, an increase in neurotransmitters such as serotonin and dopamine (responsible for regulating emotions and behavior) can be induced through exercise interventions included in MBTs (e.g., Tai Chi, Qigong, and Yoga), which help improve BPSD in OPWD (90).

BPSD represents a heterogeneous group of non-cognitive symptoms and behaviors that occur in patients with dementia, including anxiety, depression, agitation, irritability, apathy, and delusions (91-93). Therefore, in the quantitative analysis, BPSD was subdivided based on existing data to further clarify the efficacy of MBTs for these specific symptoms. Although the pooled results of the meta-analyses indicated that MBTs effectively improved BPSD in OPWD, this impact did not include all symptoms. For instance, according to the pooled results for agitation in OPWD, MBTs did not provide significant therapeutic benefits as previously assumed, which is consistent with previous evidence (30, 32). This may be because, for OPWD, especially those with advanced dementia, the inability to perform activities of daily living, often accompanied by clinical complications such as dysphagia and infections (14), presents a significant challenge in addressing behavioral disorders (including agitation and aggressive tendencies) with short-term MBTs. Finally, in terms of improving anxiety and depression in OPWD, evidence confirming the therapeutic benefits of MBTs is urgently required because of the significant heterogeneity or sensitivity to study selection in the pooled results. This may stem from the fact that the specific interventions, implementation steps, and duration of the interventions varied between studies, resulting in large differences in effect sizes. Additionally, the CIs for certain pooled results were near the threshold of statistical significance after excluding individual studies. This indicates that the sample size and experimental design need to be further increased and refined to more precisely evaluate the potential benefits of MBTs on these outcomes.

enhancing physical and mental health in OPWD, their differential efficacy should be further explored and validated. Most existing trials focus on the efficacy of a single intervention for BPSD in OPWD while ignoring the differential efficacy between various interventions. This may lead to an overestimation of the actual efficacy of MBTs in clinical practice. In the context of limited medical resources and the increasing prevalence of dementia, MBTs that can be effectively applied to clinical practice should be identified. Doctors and nurses are inclined to use nonpharmacological treatments more than pharmacological treatments in clinical practice (94). Therefore, comparisons between non-pharmacological treatments should receive more attention. A network meta-analysis suggests that individualized nursing, behavior therapy, and reminiscence therapy have significant potential in improving BPSD in OPWD, particularly in reducing anxiety and depression (95). Thus, the differential efficacy of non-pharmacological treatments in improving various aspects of BPSD should be further examined to maximize the clinical benefits of non-pharmacological treatments in the context of limited medical resources. Notably, the efficacy of MBTs in improving BPSD in OPWD may vary depending on the intervention period, frequency, and duration, suggesting that the dose-response relationship of MBTs in this regard is also an important area for investigation. Although this study did not reveal the optimal dosage of MBTs for improving BPSD in OPWD, existing research indicates that the intervention period, frequency, and duration are critical factors influencing efficacy (31, 33, 96). Short-term, high-frequency interventions may lead to faster clinical improvements to some extent, while long-term, low-frequency interventions may help maintain long-term efficacy. Therefore, more high-quality RCTs must be conducted to explore the dose-response relationship of MBTs in improving BPSD in OPWD, and intervention programs should be flexibly adjusted in clinical practice based on patients' individual differences to achieve the best therapeutic outcomes.

Although MBTs are promising complementary therapies for

5 Limitations

The findings of this systematic review and meta-analysis should be interpreted in the context of these limitations. First, owing to the limited information available on the study population from existing trials, this study mainly examined the overall therapeutic benefit of MBTs for OPWD and did not make specific distinctions based on the type and course of dementia. Second, although there was significant heterogeneity in the pooled results for some outcomes, sources of heterogeneity were not identified because of study data limitations. To address this problem, more comprehensive data should be collected in future studies. Finally, for some outcomes such as anxiety and depression, the pooled results were sensitive to study selection and were less robust; thus, the findings should be interpreted cautiously.

6 Conclusions

Effective nursing for patients with dementia is vital, as they are undergoing a major transition in their physical and mental health. Although MBTs effectively improved BPSD in OPWD to some extent, the dose-response relationship of MBTs in improving various aspects of BPSD remains unclear, and these relationships may be influenced by the intervention period, frequency, and duration. In clinical practice, healthcare and social care therapists should develop personalized intervention programs based on patient individual differences and the actual dose-response relationship, which will help maximize the clinical benefits of non-pharmacological treatments in the context of limited medical resources.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

Author contributions

ZYM: Conceptualization, Data curation, Methodology, Resources, Software, Writing – original draft, Writing – review & editing. CYC: Conceptualization, Formal analysis, Methodology, Software, Writing – original draft, Writing – review & editing. TFW: Data curation, Resources, Visualization, Writing – original draft. YZZ: Formal analysis, Validation, Writing – original draft, Software. WZ: Conceptualization, Data curation, Software, Writing – review & editing. CFL: Methodology, Software, Visualization, Writing – review & editing. SLL: Data curation, Writing – review & editing, Validation, Visualization. YS: Validation, Visualization, Writing – review & editing. SL: Funding acquisition, Methodology, Project administration, Supervision, Writing – review & editing.

References

1. Malik R, Kalra S, Bhatia S, Al Harrasi A, Singh G, Mohan S, et al. Overview of therapeutic targets in management of dementia. *Biomed Pharmacother*. (2022) 152:1–15. doi: 10.1016/j.biopha.2022.113168

2. Kornblith E, Bahorik A, Boscardin WJ, Xia F, Barnes DE, Yaffe K. Association of race and ethnicity with incidence of dementia among older adults. *JAMA*. (2022) 327:1488–95. doi: 10.1001/jama.2022.3550

3. Arvanitakis Z, Shah RC, Bennett DA. Diagnosis and management of dementia. JAMA. (2019) 322:1589-99. doi: 10.1001/jama.2019.4782

4. Grande G, Qiu C, Fratiglioni L. Prevention of dementia in an ageing world: Evidence and biological rationale. *Ageing Res Rev.* (2020) 64:101045. doi: 10.1016/ j.arr.2020.101045

5. Cao Q, Tan C-C, Xu W, Hu H, Cao X-P, Dong Q, et al. The prevalence of dementia: a systematic review and meta-analysis. *J Alzheimer's Dis.* (2020) 73:1157–66. doi: 10.3233/JAD-191092

 Licher S, Ahmad S, Karamujić-Čomić H, Voortman T, Leening MJ, Ikram MA, et al. Genetic predisposition, modifiable-risk-factor profile and long-term dementia risk in the general population. *Nat Med.* (2019) 25:1364–9. doi: 10.1038/s41591-019-0547-7

Funding

The author(s) declare that financial support was received for the research and/or publication of this article. This research was funded by the National Social Science Fund of China (project 24BTY098).

Acknowledgments

Research team would like to thank Southwest University for the support of this research, and also thank Shi Luo for the help in developing the research program.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

7. Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. *Lancet*. (2020) 396:413–46. doi: 10.1016/S0140-6736(20)30367-6

 Amariglio RE, Donohue MC, Marshall GA, Rentz DM, Salmon DP, Ferris SH, et al. Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's Disease Cooperative Study Cognitive Function Instrument. *JAMA Neurol.* (2015) 72:446–54. doi: 10.1001/jamaneurol. 2014.3375

9. Alothman D, Card T, Lewis S, Tyrrell E, Fogarty AW, Marshall CR. Risk of suicide after dementia diagnosis. *JAMA Neurol.* (2022) 79:1148-54. doi: 10.1001/jamaneurol.2022.3094

10. Stefanidou M, Beiser AS, Himali JJ, Peng TJ, Devinsky O, Seshadri S, et al. Bidirectional association between epilepsy and dementia: The Framingham Heart Study. *Neurology.* (2020) 95:e3241–e7. doi: 10.1212/WNL.000000000011077

11. Lisko I, Kulmala J, Annetorp M, Ngandu T, Mangialasche F, Kivipelto M. How can dementia and disability be prevented in older adults: where are we today and where are we going? *J Internal Med.* (2021) 289:807–30. doi: 10.1111/joim.13227

12. Becker E, Rios CLO, Lahmann C, Ruecker G, Bauer J, Boeker M. Anxiety as a risk factor of Alzheimer's disease and vascular dementia. *Br J Psychiatry*. (2018) 213:654–60. doi: 10.1192/bjp.2018.173

13. Rubin R. Exploring the relationship between depression and dementia. *JAMA*. (2018) 320:961–2. doi: 10.1001/jama.2018.11154

14. Mitchell SL. Advanced dementia. New Engl J Med. (2015) 372:2533-40. doi: 10.1056/NEJMcp1412652

15. Byun J, Lee DY, Jeong C-W, Kim Y, Rhee HY, Moon KW, et al. Analysis of treatment pattern of anti-dementia medications in newly diagnosed Alzheimer's dementia using OMOP CDM. *Sci Rep.* (2022) 12:1–9. doi: 10.1038/s41598-022-08595-1

16. Ruangritchankul S, Chantharit P, Srisuma S, Gray LC. Adverse drug reactions of acetylcholinesterase inhibitors in older people living with dementia: a comprehensive literature review. *Ther Clin Risk Manage*. (2021) 17:927–49. doi: 10.2147/TCRM.S323387

17. Zhai Y, Yin S, Zhang D. Association between antipsychotic drugs and mortality in older persons with Alzheimer's disease: a systematic review and meta-analysis. *J Alzheimer's Dis.* (2016) 52:631–9. doi: 10.3233/JAD-151207

18. Laird KT, Paholpak P, Roman M, Rahi B, Lavretsky H. Mind-body therapies for late-life mental and cognitive health. *Curr Psychiatry Rep.* (2018) 20:1–12. doi: 10.1007/s11920-018-0864-4

19. Medicine SoI. Mind-body therapies in children and youth. *Pediatrics*. (2016) 138:e1-e12. doi: 10.1542/peds.2016-1896

20. Anderson JG, Rogers CE, Bossen A, Testad I, Rose KM. Mind-body therapies in individuals with dementia: An integrative review. *Res Gerontol Nursing*. (2017) 10:288–96. doi: 10.3928/19404921-20170928-01

21. Mei Z, Jiang W, Zhang Y, Luo S, Luo S. Mind-body therapies for resilience in adolescents: A systematic review of randomized controlled trials. *Gen Hosp Psychiatry*. (2024) 91:43–51. doi: 10.1016/j.genhosppsych.2024.08.014

22. Wang Y, Tang C, Fan X, Shirai K, Dong J-Y. Mind-body therapies for older adults with dementia: a systematic review and meta-analysis. *Eur Geriatric Med.* (2022) 13:881–91. doi: 10.1007/s41999-022-00639-z

23. Karamacoska D, Tan T, Mathersul DC, Sabag A, de Manincor M, Chang D, et al. A systematic review of the health effects of yoga for people with mild cognitive impairment and dementia. *BMC Geriatrics*. (2023) 23:1–12. doi: 10.1186/s12877-023-03732-5

24. Moreno-Morales C, Calero R, Moreno-Morales P, Pintado C. Music therapy in the treatment of dementia: A systematic review and meta-analysis. *Front Med.* (2020) 7:160. doi: 10.3389/fmed.2020.00160

25. Dorris JL, Neely S, Terhorst L, VonVille HM, Rodakowski J. Effects of music participation for mild cognitive impairment and dementia: A systematic review and meta-analysis. J Am Geriatrics Soc. (2021) 69:2659–67. doi: 10.1111/jgs.17208

26. Lim KH-L, Pysklywec A, Plante M, Demers L. The effectiveness of Tai Chi for short-term cognitive function improvement in the early stages of dementia in the elderly: a systematic literature review. *Clin Interventions Aging.* (2019) 14:827–39. doi: 10.2147/CIA.S202055

27. Nyman SR, Ingram W, Sanders J, Thomas PW, Thomas S, Vassallo M, et al. Randomized controlled trial of the effect of Tai Chi on postural balance of people with dementia. *Clin Interventions Aging.* (2019) 14:2017–29. doi: 10.2147/CIA.S228931

28. Keune PM, Bernard F, Meister R, Keune J, Springer R, Arlt R, et al. Mindfulness in persons with mild dementia and their caregivers: exploring trait rumination as a clinical outcome measure. *Mindfulness.* (2023) 14:1908–17. doi: 10.1007/s12671-023-02192-7

29. Fusar-Poli L, Bieleninik Ł, Brondino N, Chen X-J, Gold C. The effect of music therapy on cognitive functions in patients with dementia: a systematic review and meta-analysis. *Aging Ment Health.* (2018) 22:1103–12. doi: 10.1080/13607863.2017.1348474

30. Han A. Mindfulness-based interventions for older adults with dementia or mild cognitive impairment: A meta-analysis. *Clin Gerontol.* (2022) 45:763–76. doi: 10.1080/07317115.2021.1995561

31. Chan J, Leung DK, Walton H, Wong GH, Spector A. Can mindfulness-based interventions benefit people with dementia? Drawing on the evidence from a systematic review in populations with cognitive impairments. *Expert Rev Neurother*. (2020) 20:1143–56. doi: 10.1080/14737175.2020.1810571

32. Wang FL, Tang QY, Zhang LL, Yang JJ, Li Y, Peng H, et al. Effects of mindfulness-based interventions on dementia patients: a meta-analysis. *West J Nurs Res.* (2020) 42:1163–73. doi: 10.1177/0193945920916750

33. Hofbauer LM, Ross SD, Rodriguez FS. Music-based interventions for community-dwelling people with dementia: A systematic review. *Health Soc Care Commun.* (2022) 30:2186–201. doi: 10.1111/hsc.13895

34. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. *Ann Internal Med.* (2015) 162:777–84. doi: 10.7326/M14-2385

35. Sterne JA, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomized trials. *BMJ*. (2019) 366:1–8. doi: 10.1136/bmj.l4898

36. Deeks JJ, Higgins JP, Altman DG. Analyzing data and undertaking metaanalyses. In: Higgins J, Thomas J, Chandler J, Cumpston M, Li TPM, Welch V, editors. *Cochrane handbook for systematic reviews of interventions*. John Wiley & Sons, Hoboken (2019). p. 241–84.

37. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*. (2003) 327:557–60. doi: 10.1136/bmj.327.7414.557

38. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ*. (1997) 315:629–34. doi: 10.1136/bmj.315.7109.629

39. Tang J-L, Liu JL. Misleading funnel plot for detection of bias in meta-analysis. J Clin Epidemiol. (2000) 53:477-84. doi: 10.1016/S0895-4356(99)00204-8

40. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. *Biometrics.* (2000) 56:455–63. doi: 10.1111/j.0006-341X.2000.00455.x

41. Guyatt GH, Oxman AD, Schünemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. *J Clin Epidemiol.* (2011) 64:380–2. doi: 10.1016/j.jclinepi.2010.09.011

42. Baker FA, Lee YC, Sousa TV, Stretton-Smith PA, Tamplin J, Sveinsdottir V, et al. Clinical effectiveness of music interventions for dementia and depression in elderly care (MIDDEL): Australian cohort of an international pragmatic cluster-randomized controlled trial. *Lancet Health Long.* (2022) 3:e153–e65. doi: 10.1016/s2666-7568(22) 00027-7

43. Ceccato E, Vigato G, Bonetto C, Bevilacqua A, Pizziolo P, Crociani S, et al. STAM protocol in dementia: A multicenter, single-blind, randomized, and controlled trial. *Am J Alzheimer's Dis other Dementias.* (2012) 27:301–10. doi: 10.1177/1533317512452038

44. Chen YL, Pei YC. Musical dual-task training in patients with mild-to-moderate dementia: A randomized controlled trial. *Neuropsychiatr Dis Treat*. (2018) 14:1381–93. doi: 10.2147/NDT.S159174

45. Cheng ST, Chow PK, Yu EC, Chan AC. Leisure activities alleviate depressive symptoms in nursing home residents with very mild or mild dementia. *Am J Geriatric Psychiatry.* (2012) 20:904–8. doi: 10.1097/JGP.0b013e3182423988

46. Cheung DSK, Lai CKY, Wong FKY, Leung MCP. Is music-with-movement intervention better than music listening and social activities in alleviating agitation of people with moderate dementia? A randomized controlled trial. *Dementia.* (2020) 19:1413–25. doi: 10.1177/1471301218800195

47. Chu H, Yang C-Y, Lin Y, Ou K-L, Lee T-Y, O'Brien AP, et al. The impact of group music therapy on depression and cognition in elderly persons with dementia: A randomized controlled study. *Biol Res Nursing*. (2014) 16:209–17. doi: 10.1177/1099800413485410

48. Cooke M, Moyle W, Shum D, Harrison S, Murfield J. A randomized controlled trial exploring the effect of music on quality of life and depression in older people with dementia. *J Health Psychol.* (2010) 15:765–76. doi: 10.1177/1359105310368188

49. Cooke ML, Moyle W, Shum DH, Harrison SD, Murfield JE. A randomized controlled trial exploring the effect of music on agitated behaviors and anxiety in older people with dementia. *Aging Ment Health*. (2010) 14:905–16. doi: 10.1080/13607861003713190

50. Guétin S, Portet F, Picot MC, Pommié C, Messaoudi M, Djabelkir L, et al. Effect of music therapy on anxiety and depression in patients with Alzheimer's type dementia: Randomized, controlled study. *Dementia Geriatric Cogn Disord.* (2009) 28:36–46. doi: 10.1159/000229024

51. Hillebrand MC, Weise L, Wilz G. Immediate effects of individualized music listening on behavioral and psychological symptoms of dementia: A randomized controlled trial. *Int J Geriatric Psychiatry.* (2023) 38:1–9. doi: 10.1002/gps.5893

52. Huang N, Li W, Rong X, Champ M, Wei L, Li M, et al. Effects of a modified Tai Chi program on older people with mild dementia: A randomized controlled trial. *J Alzheimer's Dis.* (2019) 72:947–56. doi: 10.3233/JAD-190487

53. Lin Y, Chu H, Yang C-Y, Chen C-H, Chen S-G, Chang H-J, et al. Effectiveness of group music intervention against agitated behavior in elderly persons with dementia. *Int J Geriatric Psychiatry*. (2011) 26:670–8. doi: 10.1002/gps.2580

54. Liu MN, Liou YJ, Wang WC, Su KC, Yeh HL, Lau CI, et al. Group music intervention using percussion instruments to reduce anxiety among elderly male veterans with Alzheimer disease. *Med Sci Monitor*. (2021) 27:e928714. doi: 10.12659/MSM.928714

55. Lyu J, Zhang J, Mu H, Li W, Champ M, Xiong Q, et al. The effects of music therapy on cognition, psychiatric symptoms, and activities of daily living in patients with Alzheimer's disease. *J Alzheimer's Dis.* (2018) 64:1347–58. doi: 10.3233/jad-180183

56. Park J, Tolea MI, Sherman D, Rosenfeld A, Arcay V, Lopes Y, et al. Feasibility of conducting nonpharmacological interventions to manage dementia symptoms in community-dwelling older adults: A cluster randomized controlled trial. *Am J Alzheimer's Dis Other Dementias*. (2020) 35:1–12. doi: 10.1177/1533317519872635

57. Raglio A, Bellandi D, Baiardi P, Gianotti M, Ubezio MC, Zanacchi E, et al. Effect of active music therapy and individualized listening to music on dementia: A multicenter randomized controlled trial. *J Am Geriatrics Soc.* (2015) 63:1534–9. doi: 10.1111/jgs.13558

58. Raglio A, Oasi O, Gianotti M, Manzoni V, Bolis S, C Ubezio M, et al. Effects of music therapy on psychological symptoms and heart rate variability in patients with

dementia. A pilot study Curr Aging Sci. (2010) 3:242-6. doi: 10.2174/ 1874609811003030242

59. Ridder HMO, Stige B, Qvale LG, Gold C. Individual music therapy for agitation in dementia: an exploratory randomized controlled trial. *Aging Ment Health.* (2013) 17:667–78. doi: 10.1080/13607863.2013.790926

60. Sakamoto M, Ando H, Tsutou A. Comparing the effects of different individualized music interventions for elderly individuals with severe dementia. *Int Psychoger.* (2013) 25:775–84. doi: 10.1017/s1041610212002256

61. Sing CY, Lee PHT, Leung ABK, Chung KSM, Kwok JKL, Ho RTH, et al. Managing behavioral and psychological symptoms in Chinese elderly with dementia via group-based music intervention: A cluster randomized controlled trial. *Dementia*. (2019) 18:2785–98. doi: 10.1177/1471301218760023

62. Sung HC, Chang AM, Abbey J. The effects of preferred music on agitation of older people with dementia in Taiwan. *Int J Geriatric Psychiatry*. (2006) 21:999–1000. doi: 10.1002/gps.1585

63. Sung Hc, Chang Sm, Lee Wl, Lee Ms. The effects of group music with movement intervention on agitated behaviors of institutionalized elders with dementia in Taiwan. *Complement Ther Med.* (2006) 14:113–9. doi: 10.1016/j.ctim.2006.03.002

64. Sung HC, Lee WL, Li TL, Watson R. A group music intervention using percussion instruments with familiar music to reduce anxiety and agitation of institutionalized older adults with dementia. *Int J Geriatric Psychiatry.* (2012) 27:621–7. doi: 10.1002/gps.2761

65. Xu H, Li A, Apuke OD. The impact of group music therapy in ameliorating the depression among patients with dementia in care homes: A randomized control trial. *Geriatric Nursing.* (2024) 56:304–11. doi: 10.1016/j.gerinurse.2024.02.021

66. Churcher Clarke A, Chan JMY, Stott J, Royan L, Spector A. An adapted mindfulness intervention for people with dementia in care homes: feasibility pilot study. *Int J Geriatric Psychiatry.* (2017) 32:e123–e31. doi: 10.1002/gps.4669

67. Giulietti MV, Spatuzzi R, Fabbietti P, Vespa A. Effects of mindfulness-based interventions (MBIs) in patients with early-stage Alzheimer's disease: A pilot study. *Brain Sci.* (2023) 13:1–12. doi: 10.3390/brainsci13030484

68. Harrison TC, Blozis SA, Schmidt B, Johnson A, Moreno R, Mead S, et al. Music compared with auditory books: A randomized controlled study among long-term care residents with Alzheimer's disease or related dementia. *J Am Med Direct Assoc.* (2021) 22:1415–20. doi: 10.1016/j.jamda.2021.01.086

69. McCreedy EM, Sisti A, Gutman R, Dionne L, Rudolph JL, Baier R, et al. Pragmatic trial of personalized music for agitation and antipsychotic use in nursing home residents with dementia. *J Am Med Direct Assoc.* (2022) 23:1171–7. doi: 10.1016/j.jamda.2021.12.030

70. Noone D, Payne J, Stott J, Aguirre E, Patel-Palfreman MM, Stoner C, et al. The feasibility of a mindfulness intervention for depression in people with mild dementia: A pilot randomized controlled trial. *Clin Gerontol.* (2023) 46:346–58. doi: 10.1080/07317115.2022.2094741

71. Prick AEJC, Zuidema SU, van Domburg P, Verboon P, Vink AC, Schols JMGA, et al. Effects of a music therapy and music listening intervention for nursing home residents with dementia: a randomized controlled trial. *Front Med.* (2024) 11:1304349. doi: 10.3389/fmed.2024.1304349

72. Raglio A, Bellelli G, Traficante D, Gianotti M, Ubezio MC, Gentile S, et al. Efficacy of music therapy treatment based on cycles of sessions: A randomized controlled trial. *Aging Ment Health.* (2010) 14:900–4. doi: 10.1080/13607861003713158

73. Raglio A, Bellelli G, Traficante D, Gianotti M, Ubezio MC, Villani D, et al. Efficacy of music therapy in the treatment of behavioral and psychiatric symptoms of dementia. *Alzheimer Dis Assoc Disord.* (2008) 22:158–62. doi: 10.1097/WAD.0b013e3181630b6f

74. Sisti A, Gutman R, Mor V, Dionne L, Rudolph JL, Baier RR, et al. Using structured observations to evaluate the effects of a personalized music intervention on agitated behaviors and mood in nursing home residents with dementia: results from an embedded, pragmatic randomized controlled trial. *Am J Geriatric Psychiatry.* (2024) 32:300–11. doi: 10.1016/j.jagp.2023.10.016

75. Vink AC, Zuidersma M, Boersma F, de Jonge P, Zuidema SU, Slaets JP. The effect of music therapy compared with general recreational activities in reducing agitation in people with dementia: a randomized controlled trial. *Int J Geriatric Psychiatry.* (2013) 28:1031–8. doi: 10.1002/gps.3924

76. Weise L, Töpfer NF, Deux J, Wilz G. Feasibility and effects of individualized recorded music for people with dementia: A pilot RCT study. *Nordic J Music Ther.* (2020) 29:39–56. doi: 10.1080/08098131.2019.1661507

77. Ueda T, Suzukamo Y, Sato M, Izumi S-I. Effects of music therapy on behavioral and psychological symptoms of dementia: a systematic review and meta-analysis. *Ageing Res Rev.* (2013) 12:628–41. doi: 10.1016/j.arr.2013.02.003

78. Scott S, Kidd A. A scoping review of music and anxiety, depression and agitation in older people with dementia in residential facilities and specialist care units. *Eur Geriatric Med.* (2016) 7:488–91. doi: 10.1016/j.eurger.2016.07.007

79. Ing-Randolph AR, Phillips LR, Williams AB. Group music interventions for dementia-associated anxiety: A systematic review. *Int J Nurs Stud.* (2015) 52:1775–84. doi: 10.1016/j.ijnurstu.2015.06.014

80. Tsoi KK, Chan JY, Ng Y-M, Lee MM, Kwok TC, Wong SY. Receptive music therapy is more effective than interactive music therapy to relieve behavioral and psychological symptoms of dementia: a systematic review and meta-analysis. *J Am Med Direct Assoc.* (2018) 19:568–76. e3. doi: 10.1016/j.jamda.2017.12.009

81. Zhang Y, Cai J, An L, Hui F, Ren T, Ma H, et al. Does music therapy enhance behavioral and cognitive function in elderly dementia patients? A systematic review and meta-analysis. *Ageing Res Rev.* (2017) 35:1–11. doi: 10.1016/j.arr.2016.12.003

82. Mei Z, Zhang Y, Zhao W, Lam C, Luo S, Wang S, et al. Music-based interventions for anxiety and depression in older adults with dementia: A systematic review of randomized controlled trials. *Complement Ther Clin Pract.* (2025) 59:1–8. doi: 10.1016/j.ctcp.2025.101951

83. Milligan Armstrong A, Porter T, Quek H, White A, Haynes J, Jackaman C, et al. Chronic stress and A lzheimer's disease: the interplay between the hypothalamicpituitary-adrenal axis, genetics and microglia. *Biol Rev.* (2021) 96:2209–28. doi: 10.1111/brv.12750

84. Hafizi S, Rajji TK. Modifiable risk factors of dementia linked to excitationinhibition imbalance. *Ageing Res Rev.* (2023) 83:1–10. doi: 10.1016/j.arr.2022.101804

85. Taylor AG, Goehler LE, Galper DI, Innes KE, Bourguignon C. Top-down and bottom-up mechanisms in mind-body medicine: development of an integrative framework for psychophysiological research. *Explore*. (2010) 6:29–41. doi: 10.1016/ j.explore.2009.10.004

86. Lindsay EK, Young S, Smyth JM, Brown KW, Creswell JD. Acceptance lowers stress reactivity: Dismantling mindfulness training in a randomized controlled trial. *Psychoneuroendocrinology*. (2018) 87:63–73. doi: 10.1016/j.psyneuen.2017.09.015

87. Nyklíček I, Mommersteeg P, Van Beugen S, Ramakers C, Van Boxtel GJ. Mindfulness-based stress reduction and physiological activity during acute stress: a randomized controlled trial. *Health Psychol.* (2013) 32:1110–3. doi: 10.1037/a0032200

88. Pant U, Frishkopf M, Park T, Norris CM, Papathanassoglou E. A neurobiological framework for the therapeutic potential of music and sound interventions for post-traumatic stress symptoms in critical illness survivors. *Int J Environ Res Public Health*. (2022) 19:1–19. doi: 10.3390/ijerph19053113

89. Gothe NP, Keswani RK, McAuley E. Yoga practice improves executive function by attenuating stress levels. *Biol Psychol.* (2016) 121:109-16. doi: 10.1016/j.biopsycho.2016.10.010

90. Matura S, Carvalho A F, Alves G S, Pantel J. Physical exercise for the treatment of neuropsychiatric disturbances in Alzheimer's dementia: possible mechanisms, current evidence and future directions. *Curr Alzheimer Res.* (2016) 13:1112–23. doi: 10.2174/1567205013666160502123428

91. Lawlor B. Managing behavioral and psychological symptoms in dementia. Br J Psychiatry. (2002) 181:463-5. doi: 10.1192/bjp.181.6.463

92. Azermai M, Petrovic M, Elseviers MM, Bourgeois J, Van Bortel LM, Vander Stichele RH. Systematic appraisal of dementia guidelines for the management of behavioral and psychological symptoms. *Ageing Res Rev.* (2012) 11:78–86. doi: 10.1016/j.arr.2011.07.002

93. Cerejeira J, Lagarto L, Mukaetova-Ladinska EB. Behavioral and psychological symptoms of dementia. *Front Neurol.* (2012) 3:73. doi: 10.3389/fneur.2012.00073

94. Janus SI, van Manen JG, Van Til JA, Zuidema SU, IJzerman MJ. Pharmacological and non-pharmacological treatment preferences of healthcare professionals and proxies for challenging behaviors in patients with dementia. *Int Psychoger.* (2017) 29:1377–89. doi: 10.1017/S1041610217000485

95. Li W, Xu X, Wu F, Ni Y, Lan J, Hu X. Comparative efficacy of non-pharmacological interventions on behavioral and psychological symptoms in elders with dementia: A network meta-analysis. *Nurs Open.* (2021) 8:2922–31. doi: 10.1002/nop2.1049

96. Brenes GA, Sohl S, Wells RE, Befus D, Campos CL, Danhauer SC. The effects of yoga on patients with mild cognitive impairment and dementia: A scoping review. *Am J Geriatric Psychiatry.* (2019) 27:188–97. doi: 10.1016/j.jagp.2018.10.013